Medical weight loss in San Diego
Struggling with weight loss? This programme may be the breakthrough you have been waiting for. It combines medication with nutrition and an exercise plan, under the supervision of a board-certified physician.
The medications were originally developed to manage type 2 diabetes and are now recognised for their weight-loss benefits. Studies show they help people lose a significant amount of weight — a genuine change in what medicine can offer for obesity.
What the medication is
The medication belongs to a class of drugs called GLP-1 receptor agonists (glucagon-like peptide-1), and to a related class, the GLP-1/GIP (glucose-dependent insulinotropic polypeptide) dual agonists. Both have shown promising results in helping people reach and maintain a healthier weight.
Development of these medications for weight loss reflects an ongoing effort in medical research to find effective and safe solutions to the global challenge of obesity. They have undergone rigorous testing for safety and efficacy, resulting in approval for weight management by healthcare regulatory authorities.
How it works
The medication mimics the action of a naturally occurring hormone called GLP-1, which helps regulate blood sugar and appetite.
When administered it stimulates the release of one hormone, reduces the production of another, and slows the rate at which the stomach empties. Together these actions produce weight loss by promoting a feeling of fullness, reducing food intake, and improving glucose receptor sensitivity.
What the results look like
GLP-1 and dual agonist weight-loss treatments produce significant reductions in body weight. According to current studies, GLP-1 mono-agonists show average losses of up to 15% at 68 weeks, and GLP-1/GIP dual agonists demonstrate even greater effects — up to 22.5% at 72 weeks.
Those are trial averages over more than a year of treatment, not a promise about any individual. Your trajectory depends on your starting point, your dose, your nutrition and your activity — which is exactly why the medication is one part of a programme rather than the whole of it.
Common side effects
Gastrointestinal issues — nausea, vomiting, diarrhoea, constipation, bloating and abdominal pain are the most frequent effects, and are usually most pronounced when starting the medication or increasing the dose. They are managed by eating smaller and more frequent meals, staying well hydrated, avoiding fatty, fried or spicy foods, and eating bland foods during a flare-up.
Reduced appetite and muscle loss — reduced appetite and a feeling of fullness are the intended effect, and can produce significant weight loss. Without proper nutritional intake and exercise, however, that loss can include a considerable amount of lean muscle mass.
Injection site reactions — mild, temporary redness, itching or swelling can occur, and are managed by rotating injection sites and applying a cool compress.
Other common effects — headaches, fatigue, dizziness, or a temporary increase in resting heart rate.
Serious side effects and precautions
Thyroid C-cell tumours — many GLP-1 medications carry an FDA boxed warning for a potential risk of thyroid C-cell tumours based on animal studies. People with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2, should not use these drugs. The risk in humans remains under investigation and some recent studies have found no significant link.
Pancreatitis — GLP-1s have been linked to a rare risk of acute pancreatitis. Patients with a history of pancreatitis should be closely monitored or may need to avoid these medications. Severe, persistent abdominal pain that may radiate to the back, with or without vomiting, is a sign of pancreatitis and requires immediate medical attention.
Gallbladder disease — an increased risk of gallstones or an inflamed gallbladder, more likely with rapid weight loss. Severe upper-right abdominal pain, nausea and jaundice can be symptoms.
Kidney injury — severe gastrointestinal effects such as persistent vomiting and diarrhoea can lead to dehydration and, rarely, acute kidney injury. Stay well hydrated and seek medical help for severe digestive symptoms.
Gastroparesis — GLP-1s slow stomach emptying by design, but in some cases this can become a serious condition causing persistent nausea, vomiting and a feeling of fullness.
Hypoglycaemia — the risk of low blood sugar is low with GLP-1s alone, but increases significantly in combination with other diabetes medications such as insulin or sulfonylureas.
Allergic reactions — serious hypersensitivity reactions including anaphylaxis can occur, though they are rare. Signs include swelling of the face, lips or throat, hives, or difficulty breathing.
Increased risk during anaesthesia — because GLP-1s slow digestion there is an increased risk of pulmonary aspiration during surgery or deep sedation. Tell your doctor you are taking one; you may need to stop it for a period before a procedure involving general anaesthesia.
Who should not take a GLP-1
You should not take GLP-1 medications if you have:
A personal or family history of medullary thyroid carcinoma (MTC)
A diagnosis of multiple endocrine neoplasia syndrome type 2 (MEN2)
Had a serious allergic reaction to a GLP-1 agonist or any of its ingredients
Pregnancy or breastfeeding
Why supervision matters
Every item in the two lists above is a reason this is a prescription medication managed by a physician rather than a product you order. The dose is titrated upward over time, side effects are managed as they appear, and the contraindications have to be ruled out before the first injection — not discovered after it.
Consultation is with a board-certified physician in our clinic. We are running a promotional first-month rate for the programme that includes that consultation.
Questions about medical weight loss
What medication does the programme use?
The programme uses GLP-1 receptor agonists and GLP-1/GIP dual agonists. The specific medication and dose are determined at your consultation with the physician, based on your medical history and your goals.
How much weight can I expect to lose?
According to current studies, GLP-1 mono-agonists show average body-weight losses of up to 15% at 68 weeks, and GLP-1/GIP dual agonists up to 22.5% at 72 weeks. Those are averages across trial populations over more than a year of continuous treatment, not a prediction for any individual.
Will I lose muscle as well as fat?
You can. Reduced appetite is the intended effect of the medication, and without adequate protein intake and resistance exercise a considerable proportion of the weight lost can be lean muscle mass. This is the main reason the programme pairs medication with nutrition and exercise rather than prescribing in isolation.
What are the most common side effects?
Gastrointestinal — nausea, vomiting, diarrhoea, constipation, bloating and abdominal pain. They are usually most pronounced when starting the medication or increasing the dose, and are managed with smaller and more frequent meals, good hydration, and avoiding fatty, fried or spicy foods.
Who should not take these medications?
Anyone with a personal or family history of medullary thyroid carcinoma, a diagnosis of multiple endocrine neoplasia syndrome type 2, a previous serious allergic reaction to a GLP-1 agonist or its ingredients, or who is pregnant or breastfeeding.
Do I need to tell a surgeon or anaesthetist that I am taking one?
Yes. Because GLP-1s slow digestion there is an increased risk of pulmonary aspiration during surgery or deep sedation, and you may need to stop the medication for a period before any procedure involving general anaesthesia.
Is the consultation with a doctor?
Yes. Consultation is with a board-certified physician in our clinic, and the promotional first-month rate for the programme includes it.
Stanislav Zayets, MD
Board-certified — American Board of Internal Medicine
Last reviewed August 7, 2026
Your consultation is free.
Tell us what you're considering and we'll tell you honestly whether medical weight loss is the right treatment for it.